Breaking News
October 24, 2018 - Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer
October 24, 2018 - Analysis of largest set of genomes from pregnant women reveals genetic links to disease, birth outcomes
October 24, 2018 - New vaccine strategy shows promise to protect chickens against serious respiratory disease
October 24, 2018 - First Asia Reference Center in Singapore
October 24, 2018 - New partnership aims to tackle cancer health disparities
October 24, 2018 - Two Roche Diagnostic tests identified as transformative
October 24, 2018 - Cocaine overdoses on the rise with fentanyl combo flooding the market
October 24, 2018 - Radiotherapy combined with androgen-deprivation therapy improves overall survival up to 10 years
October 24, 2018 - Spectrum Pharmaceuticals Receives FDA Approval of Khapzory (levoleucovorin) for Injection
October 24, 2018 - Researcher uses smartphone to detect breast cancer gene
October 24, 2018 - Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination
October 24, 2018 - Stress related to social stigma negatively impacts mental health of autistic people
October 24, 2018 - New 17-item questionnaire may help detect GI disorders in children with autism
October 24, 2018 - 12% of frequent marijuana smokers experience cannabis withdrawal syndrome
October 24, 2018 - Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis
October 24, 2018 - Poor Experience With PCP Linked to Hospitalization in CKD
October 23, 2018 - Dummies not to blame for common speech disorder in kids
October 23, 2018 - The future of ethics and biomedicine: An interview
October 23, 2018 - X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma
October 23, 2018 - FDA targets 465 websites that sell potentially dangerous, unapproved drugs
October 23, 2018 - New approach may lead to better diagnostic techniques for autoimmune disorders
October 23, 2018 - Innovative computer software sheds new light on genetic processes underlying deadly diseases
October 23, 2018 - Juul Drawing Lots of Teen Followers on Twitter
October 23, 2018 - WHO says Zika risk low in Pacific ahead of Meghan visit
October 23, 2018 - A deeper look at ‘Reflecting Frankenstein’
October 23, 2018 - Breastfeeding can have protective affect against high blood pressure in women, confirms study
October 23, 2018 - Epigenetic modifications may contribute to Alzheimer’s Disease
October 23, 2018 - Volunteering for peer counseling programs benefits people with lupus
October 23, 2018 - Cancer treatment may undergo a paradigm shift to immunotherapy soon
October 23, 2018 - Study uncovers new mechanism of action in a first-line drug for diabetes
October 23, 2018 - New type of molecule shows early promise against treatment-resistant prostate cancer
October 23, 2018 - Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients
October 23, 2018 - Scientists grow functioning human neural networks in 3D from stem cells
October 23, 2018 - Using mushrooms as a prebiotic may help improve glucose regulation
October 23, 2018 - New ENT clinic treats children in Zimbabwe
October 23, 2018 - CUIMC Celebrates 2018-2019, Issue 2
October 23, 2018 - Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer
October 23, 2018 - Intake of painkillers during pregnancy linked to early puberty in future offspring
October 23, 2018 - ConnectToBrain project seeks to improve techniques for brain stimulation in current clinical use
October 23, 2018 - Polyganics begins first-in-human clinical trial of LIQOSEAL for reducing CSF leakage
October 23, 2018 - Gut bacterial community of healthy adults recovers after short-term exposure to broad-spectrum antibiotics
October 23, 2018 - Lowering systolic blood pressure does not damage the kidneys, shows study
October 23, 2018 - Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis
October 23, 2018 - Cardiovascular admissions more common among most deprived
October 23, 2018 - Targeted drug and hormone therapy combination extends breast cancer survival
October 23, 2018 - Map of human liver cells reveals molecular make-up of individual cells
October 23, 2018 - Drugs approved for breast cancer treatment are effective and well tolerated in men
October 23, 2018 - EKF introduces new hand-held lactate analyzer for rapid sports performance monitoring
October 23, 2018 - Researchers identify common genetic connection in lung conditions
October 23, 2018 - Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC
October 23, 2018 - Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer
October 23, 2018 - New discovery may lead to better treatment options for pancreatic cancer patients
October 23, 2018 - FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma
October 23, 2018 - Researchers identify immune culprits linked to inflammation and bone loss in gum disease
October 23, 2018 - Despite lower risk factors, black men have higher rates of recidivism
October 23, 2018 - Study finds why pregnant women in mainland China, Hong Kong and Taiwan prefer cesarean delivery
October 23, 2018 - AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis
October 23, 2018 - NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors
October 23, 2018 - Scientists use electron microscope to study chemical transformation in catalytic cross-coupling reaction
October 23, 2018 - Research offers new hope to men who received childhood cancer treatment
October 23, 2018 - New medical navigation system receives international innovation award
October 23, 2018 - Adverse Childhood Experiences Tied to Burnout in BSN Students
October 23, 2018 - High levels of oral disease among elite athletes affecting performance
October 23, 2018 - Study examines effect of immediate vs delayed pushing during labor on delivery outcomes
October 23, 2018 - LU-RRTC to spearhead capacity-building efforts for racial and ethnic populations
October 23, 2018 - Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients
October 23, 2018 - Organic food may protect against cancers finds study
October 23, 2018 - Interweaving anxiety disorder associated with stuttering remains unrecognized
October 23, 2018 - Cannabis oil shown to significantly improve Crohn’s disease symptoms
October 23, 2018 - Knowledge of sex differences in lower urinary tract may help stimulate breakthroughs in diagnosis, management
October 23, 2018 - Common antibodies associated with myocardial infarction
October 23, 2018 - Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy
October 23, 2018 - Brain’s ‘Self-Control’ Center May Be Key to Weight-Loss Success
October 23, 2018 - Prosthetic valve mismatches common in transcatheter valve replacement, ups risk of death
October 23, 2018 - Can virtual reality help people become more compassionate?
October 23, 2018 - Screen time eclipsed outdoor time for most students, shows study
October 23, 2018 - SLU researcher seeks to find solutions for ‘chemo brain’ symptoms and side effects of opioids
October 23, 2018 - Plastics now commonly found in human stools
October 23, 2018 - Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer
October 23, 2018 - Cancer survivors at risk for heart failure during, after pregnancy
Genetic testing of prostate tumors could identify likely responders to immunotherapy

Genetic testing of prostate tumors could identify likely responders to immunotherapy

image_pdfDownload PDFimage_print

Scientists have identified a pattern of genetic changes that could pick out men with advanced prostate cancer who are likely to benefit from immunotherapy.

Developing a genetic test to pick out these men could speed up the path of immunotherapy into use for prostate cancer patients.

A major clinical trial earlier this month became the first to show that immunotherapy could work in advanced prostate cancer – but only for about 10 per cent of men.

Now the new study, involving scientists at The Institute of Cancer Research, London, has discovered that testing the genetics of prostate tumors could identify the likely responders.

The research, published today (Thursday) in the prestigious journal Cell, found that men whose tumors had a distinct pattern of genetic changes could be much more likely to benefit from immunotherapy than otherwise.

The study was supported by funders including the Prostate Cancer Foundation and Stand Up 2 Cancer.

Scientists at The Institute of Cancer Research (ICR) worked with colleagues at the University of Michigan in the US to analyze tumor DNA collected internationally from 360 men with advanced prostate cancer that had spread.

They found that the tumors of 7 per cent of these men were missing both copies of a gene called CDK12, a trait that was linked with a unique pattern of additional genetic changes.

Tumors with this genetic profile contained a higher number of immune cells than other forms of advanced prostate cancer.

They also had a higher number of protein fragments on their surface, called neoantigens, which flag tumor cells to the immune system. Tumors that are associated with large numbers of immune cells and neoantigens often respond better to immunotherapy, presumably because the immune system has already begun to recognize elements of the cancer as foreign.

In a small pilot clinical study carried out in the US as part of the research, two out of four men with advanced prostate cancer whose tumors had CDK12-linked genetic changes responded remarkably well to the immunotherapy drug pembrolizumab.

It follows the results of a clinical trial led by the ICR and The Royal Marsden NHS Foundation Trust which showed pembrolizumab could benefit a subset of patients with advanced prostate cancer who had run out of existing treatment options.

In the new study, the pattern of genetic changes linked with the missing copies of the CDK12 gene was distinct from other, previously identified genetic subtypes of prostate cancer, making this an entirely separate form of the disease.

If the research can be replicated in larger numbers of patients, it could lead to introduction of a genetic test as a precursor to offering immunotherapy.

In future, CDK12 could also be explored as a genetic weakness that could be targeted by new precision drugs for prostate cancer. Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, said:

“Immunotherapy works for a relatively small group of men with advanced prostate cancer – but when it works, it really works. If we can identify in advance who will benefit, then it should accelerate the passage of immunotherapy into routine use for patients.

“Our new study has revealed a distinct group of men with advanced prostate cancer whose tumors have biological features that could make them likely to respond to immunotherapy drugs such as pembrolizumab.

“We now need larger clinical studies to further study the benefit of immunotherapy in this group of patients. In the future, a genetic test could help pick out men with this particular set of genetic changes, so that they can be considered for immunotherapy.”

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

“Increasing our understanding of the biological and genetic features of cancer is vital in the search for smarter, kinder cancer treatments.

“It’s exciting that this study may have cracked the underlying biology of why only some men with prostate cancer appear to respond well to immunotherapy.

“I look forward to this work being taken forward as soon as possible with the aim of ensuring that some men with prostate cancer can start having the same kinds of benefit from immunotherapy that we are seeing in other tumor types.”

Howard Soule, Ph.D., executive vice president and chief science officer of the Prostate Cancer Foundation, said:

“The identification of CDK12 loss as a possible biomarker for identifying prostate cancer patients who may respond to checkpoint immunotherapy is a hugely significant finding, as researchers have struggled with how to effectively use immunotherapy in prostate cancer for many years.

Source:

https://www.icr.ac.uk/news-archive/gene-testing-could-identify-men-with-prostate-cancer-who-may-benefit-from-immunotherapy

Tagged with:

About author

Related Articles